- Home
- EARN vs AARD Comparison
EARN vs AARD Comparison
Compare EARN & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- AARD
- Stock Information
- Founded
- EARN 2012
- AARD 2017
- Country
- EARN United States
- AARD United States
- Employees
- EARN N/A
- AARD N/A
- Industry
- EARN Real Estate Investment Trusts
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- EARN Real Estate
- AARD Health Care
- Exchange
- EARN Nasdaq
- AARD Nasdaq
- Market Cap
- EARN 187.6M
- AARD 154.9M
- IPO Year
- EARN 2013
- AARD 2025
- Fundamental
- Price
- EARN $5.62
- AARD $10.44
- Analyst Decision
- EARN Buy
- AARD Strong Buy
- Analyst Count
- EARN 2
- AARD 4
- Target Price
- EARN $5.88
- AARD $31.25
- AVG Volume (30 Days)
- EARN 355.9K
- AARD 50.1K
- Earning Date
- EARN 05-20-2025
- AARD 05-14-2025
- Dividend Yield
- EARN 17.08%
- AARD N/A
- EPS Growth
- EARN N/A
- AARD N/A
- EPS
- EARN N/A
- AARD N/A
- Revenue
- EARN $34,563,000.00
- AARD N/A
- Revenue This Year
- EARN N/A
- AARD N/A
- Revenue Next Year
- EARN $16.66
- AARD N/A
- P/E Ratio
- EARN N/A
- AARD N/A
- Revenue Growth
- EARN 37.99
- AARD N/A
- 52 Week Low
- EARN $4.33
- AARD $4.88
- 52 Week High
- EARN $7.20
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- EARN 53.40
- AARD N/A
- Support Level
- EARN $5.33
- AARD N/A
- Resistance Level
- EARN $5.68
- AARD N/A
- Average True Range (ATR)
- EARN 0.12
- AARD 0.00
- MACD
- EARN 0.01
- AARD 0.00
- Stochastic Oscillator
- EARN 70.73
- AARD 0.00
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.